Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Blood|July 19, 2022
Loss of COP9 signalosome genes at 2q37 is associated with IMiD resistance in multiple myelomaSarah Gooding, Naser Ansari-Pour, Mohammad Kazeroun, et al.
Blood|May 12, 2026
Mezigdomide reverses T-cell exhaustion through degradation of IKZF1/IKZF3 and reinvigoration of cytokine production pathwaysHsiling Chiu, Junfei Zhao, Tara Basavanhally, et al.
British Journal of Haematology|January 22, 2022
Immune response to COVID-19 vaccination is attenuated by poor disease control and antimyeloma therapy with vaccine driven divergent T-cell responseKarthik Ramasamy, Ross Sadler, Sally Jeans, et al.
Cancers|January 8, 2023
Prospective Assessment of Tumour Burden and Bone Disease in Plasma Cell Dyscrasias Using DW-MRI and Exploratory Bone BiomarkersGaurav Agarwal, Guido Nador, Sherin Varghese, et al.
European Journal of Haematology|December 20, 2023
Determinants of durable humoral and T cell immunity in myeloma patients following COVID-19 vaccinationClement Twumasi, Sally Moore, Ross Sadler, et al.
Nature Communications|October 6, 2019
Transcriptomic profiling of the myeloma bone-lining niche reveals BMP signalling inhibition to improve bone diseaseSarah Gooding, Sam W Z Olechnowicz, Emma V Morris, et al.
Transplantation and Cellular Therapy|May 23, 2022
Proceedings from the Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Immune and Cellular Therapy in Multiple MyelomaSarah A Holstein, Fotis Asimakopoulos, Abdel Kareem Azab, et al.
Cell Stem Cell|February 24, 2026
comBO: A combined human bone and lympho-myeloid bone marrow organoid for preclinical modeling of hematopoietic disordersYuqi Shen, Camelia Benlabiod, Edmund Watson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 6, 2022
Myeloma Genome Project Panel is a Comprehensive Targeted Genomics Panel for Molecular Profiling of Patients with Multiple MyelomaParvathi Sudha, Aarif Ahsan, Cody Ashby, et al.
Blood|May 8, 2026
Ikaros degradation by mezigdomide reduces T-cell dysfunction and improves the efficacy of antimyeloma T-cell therapiesLucia Y Chen, Adolfo Aleman, Marta Larrayoz, et al.
Pageof 4